TNBC affects around 170,000 patients worldwide each year and accounts for 15-20% of breast cancer; compared to other types of breast cancer, TNBC is more aggressive and precocious. Its diagnosis, made difficult by the existence of subtypes with different characteristics, is fundamental to establish prognosis and personalized therapy. Nucleic acid aptamers are highly selective low-molecular-weight molecules, synthesizable at low cost and easily modifiable, capable of binding and detecting tissue markers ("aptahistochemistry”). Our team has iden
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 16 - 18 of 18
We present a new concept of ultra-compact, configurable and implantable brain computer interface (BCI). The device can be applied to monitor or stimulate, with high temporal and spatial accuracy, neural activity of the brain. It allows implementation of closed-loop algorithms in real time applications. The system can be also used in vitro to monitor or induce cell growth or as tDCS tool. The system can be customized (microelectrodes materials and shapes) to guarantee the best solution for the specific application.
We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.